We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Teva bulks up with injectibles

3 November 2003 By Robert Cyran

Israeli generic drugs company Teva’s $3.4bn merger with Sicor positions it to take advantage of proposed changes in biotech patent law. Euro drugs makers Roche and Serono better look out.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)